GlobeNewswire Clinical StudiesOriginal article
VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial
Trial StartVisONEPositive
AI Analysis
Summary
VisCardia implanted the first U.S. patient in the RECOVER-HF pivotal trial evaluating VisONE Synchronized Diaphragmatic Stimulation Therapy for heart failure with reduced ejection fraction. The therapy has received FDA Breakthrough Device Designation.
Clinical Trial Data
Phase
pivotal
Patients
1
Outcome Details
First U.S. patient implanted in RECOVER-HF pivotal trial
Importance:6/10
Sentiment:
0.70
heart failuremedical deviceFDA Breakthrough Device DesignationIDEdiaphragmatic stimulation
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 9, 2026 12:00 PM